Sanofi has received orphan designation from the European Medicines Agency (EMA) for rilzabrutinib, a reversible covalent ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria Late-breaking data at 2024 AAAAI ...

A new study published in the Journal of American Medical Association found that Rilzabrutinib decreased itching and hives ...

Data from the positive Phase 2 study evaluating rilzabrutinib for the treatment of IgG4-related disease presented at EULAR 2025Additional orphan designation underscores Sanofi commitment to advancing ...

Rilzabrutinib is an investigational, oral, reversible Bruton tyrosine kinase (BTK) inhibitor. Preclinical findings show the drug reduces vaso-occlusion, markers of inflammation, and adhesion in ...

Rilzabrutinib is currently under regulatory review in the US and the EU, with a US Food and Drug Administration target action date of August 29, 2025. Dietmar Berger, MD, PhD ...

Rilzabrutinib, an oral Bruton’s tyrosine kinase (BTK) inhibitor, has been granted Fast Track designation by the Food and Drug Administration (FDA) for the treatment of immune thrombocytopenia (ITP).

Rilzabrutinib also led to significant improvements in bleeding (based on the Immune Thrombocytopenic Purpura Bleeding Score), with a mean change from baseline at week 25 of –0.04 with ...

SAN DIEGO — Rilzabrutinib treatment led to rapid, stable and durable platelet responses among patients with relapsed immune thrombocytopenia, according to data presented at ASH Annual Meeting ...

Rilzabrutinib was added to Sanofi’s pipeline with the acquisition of Principia Biopharma. The candidate is also being developed in mid-stage studies for other immune-mediated diseases like ...

Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease Data from the positive Phase 2 study evaluating rilzabrutinib for the treatment of IgG4-related disease presented at ...